Relevant bibliographies by topics / Nanoparticle-based vaccines

Academic literature on the topic 'Nanoparticle-based vaccines'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nanoparticle-based vaccines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nanoparticle-based vaccines"

1

Heuts, Jeroen, Wim Jiskoot, Ferry Ossendorp, and Koen van der Maaden. "Cationic Nanoparticle-Based Cancer Vaccines." Pharmaceutics 13, no. 5 (April 21, 2021): 596. http://dx.doi.org/10.3390/pharmaceutics13050596.

Full text
Abstract:
Cationic nanoparticles have been shown to be surprisingly effective as cancer vaccine vehicles in preclinical and clinical studies. Cationic nanoparticles deliver tumor-associated antigens to dendritic cells and induce immune activation, resulting in strong antigen-specific cellular immune responses, as shown for a wide variety of vaccine candidates. In this review, we discuss the relation between the cationic nature of nanoparticles and the efficacy of cancer immunotherapy. Multiple types of lipid- and polymer-based cationic nanoparticulate cancer vaccines with various antigen types (e.g., mRNA, DNA, peptides and proteins) and adjuvants are described. Furthermore, we focus on the types of cationic nanoparticles used for T-cell induction, especially in the context of therapeutic cancer vaccination. We discuss different cationic nanoparticulate vaccines, molecular mechanisms of adjuvanticity and biodistribution profiles upon administration via different routes. Finally, we discuss the perspectives of cationic nanoparticulate vaccines for improving immunotherapy of cancer.
APA, Harvard, Vancouver, ISO, and other styles
2

Stephens, Laura M., and Steven M. Varga. "Nanoparticle vaccines against respiratory syncytial virus." Future Virology 15, no. 11 (November 2020): 763–78. http://dx.doi.org/10.2217/fvl-2020-0174.

Full text
Abstract:
Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in infants, the elderly and immunocompromised individuals. Despite the global burden, there is no licensed vaccine for RSV. Recent advances in the use of nanoparticle technology have provided new opportunities to address some of the limitations of conventional vaccines. Precise control over particle size and surface properties enhance antigen stability and prolong antigen release. Particle size can also be modified to target specific antigen-presenting cells in order to induce specific types of effector T-cell responses. Numerous nanoparticle-based vaccines are currently being evaluated for RSV including inorganic, polymeric and virus-like particle-based formulations. Here, we review the potential advantages of using different nanoparticle formulations in a vaccine for RSV, and discuss many examples of safe, and effective vaccines currently in both preclinical and clinical stages of testing.
APA, Harvard, Vancouver, ISO, and other styles
3

Marasini, Nirmal, Mariusz Skwarczynski, and Istvan Toth. "Intranasal delivery of nanoparticle-based vaccines." Therapeutic Delivery 8, no. 3 (March 2017): 151–67. http://dx.doi.org/10.4155/tde-2016-0068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Marasini, Nirmal, Mariusz Skwarczynski, and Istvan Toth. "Oral delivery of nanoparticle-based vaccines." Expert Review of Vaccines 13, no. 11 (August 26, 2014): 1361–76. http://dx.doi.org/10.1586/14760584.2014.936852.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bezbaruah, Rajashri, Vivek P. Chavda, Lawandashisha Nongrang, Shahnaz Alom, Kangkan Deka, Tutumoni Kalita, Farak Ali, Bedanta Bhattacharjee, and Lalitkumar Vora. "Nanoparticle-Based Delivery Systems for Vaccines." Vaccines 10, no. 11 (November 17, 2022): 1946. http://dx.doi.org/10.3390/vaccines10111946.

Full text
Abstract:
Vaccination is still the most cost-effective way to combat infectious illnesses. Conventional vaccinations may have low immunogenicity and, in most situations, only provide partial protection. A new class of nanoparticle-based vaccinations has shown considerable promise in addressing the majority of the shortcomings of traditional and subunit vaccines. This is due to recent breakthroughs in chemical and biological engineering, which allow for the exact regulation of nanoparticle size, shape, functionality, and surface characteristics, resulting in improved antigen presentation and robust immunogenicity. A blend of physicochemical, immunological, and toxicological experiments can be used to accurately characterize nanovaccines. This narrative review will provide an overview of the current scenario of the nanovaccine.
APA, Harvard, Vancouver, ISO, and other styles
6

Du, Lanying, Yang Yang, Xiujuan Zhang, and Fang Li. "Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies." Nanoscale 14, no. 4 (2022): 1054–74. http://dx.doi.org/10.1039/d1nr03831a.

Full text
Abstract:
This review summarizes the nanotechnology-based COVID-19 vaccines and therapeutics, including protein nanoparticle-based vaccines, lipid nanoparticle-formulated mRNA vaccines, and nanobodies as unique therapeutic antibodies.
APA, Harvard, Vancouver, ISO, and other styles
7

Bernasconi, Valentina, Karin Norling, Marta Bally, Fredrik Höök, and Nils Y. Lycke. "Mucosal Vaccine Development Based on Liposome Technology." Journal of Immunology Research 2016 (2016): 1–16. http://dx.doi.org/10.1155/2016/5482087.

Full text
Abstract:
Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital tract administration. At present, only few mucosal vaccines are found on the market, but recent technological advancements and a better understanding of the principles that govern priming of mucosal immune responses have contributed to a more optimistic view on the future of mucosal vaccines. Compared to live attenuated vaccines, subcomponent vaccines, most often protein-based, are considered safer, more stable, and less complicated to manufacture, but they require the addition of nontoxic and clinically safe adjuvants to be effective. In addition, another limiting factor is the large antigen dose that usually is required for mucosal vaccines. Therefore, the combination of mucosal adjuvants with the recent progress in nanoparticle technology provides an attractive solution to these problems. In particular, the liposome technology is ideal for combining protein antigen and adjuvant into an effective mucosal vaccine. Here, we describe and discuss recent progress in nanoparticle formulations using various types of liposomes that convey strong promise for the successful development of the next generation of mucosal vaccines.
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Naru, Qianting Ji, Zezhong Liu, Kaiming Tang, Yubin Xie, Kangchen Li, Jie Zhou, et al. "Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant." Viruses 14, no. 3 (February 28, 2022): 501. http://dx.doi.org/10.3390/v14030501.

Full text
Abstract:
The global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become more serious because of the continuous emergence of variants of concern (VOC), thus calling for the development of broad-spectrum vaccines with greater efficacy. Adjuvants play important roles in enhancing the immunogenicity of protein-based subunit vaccines. In this study, we compared the effect of three adjuvants, including aluminum, nanoparticle manganese and MF59, on the immunogenicity of three protein-based COVID-19 vaccine candidates, including RBD-Fc, RBD and S-trimer. We found that the nanoparticle manganese adjuvant elicited the highest titers of SARS-CoV-2 RBD-specific IgG, IgG1 and IgG2a, as well as neutralizing antibodies against infection by pseudotyped SARS-CoV-2 and its Delta variant. What is more, the nanoparticle manganese adjuvant effectively reduced the viral load of the authentic SARS-CoV-2 and Delta variant in the cell culture supernatants. These results suggest that nanoparticle manganese, known to facilitate cGAS-STING activation, is an optimal adjuvant for protein-based COVID-19 subunit vaccines.
APA, Harvard, Vancouver, ISO, and other styles
9

Sung, Hyo-Dong, Nayeon Kim, Yeram Lee, and Eun Jung Lee. "Protein-Based Nanoparticle Vaccines for SARS-CoV-2." International Journal of Molecular Sciences 22, no. 24 (December 14, 2021): 13445. http://dx.doi.org/10.3390/ijms222413445.

Full text
Abstract:
The pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has upended healthcare systems and economies around the world. Rapid understanding of the structural biology and pathogenesis of SARS-CoV-2 has allowed the development of emergency use or FDA-approved vaccines and various candidate vaccines. Among the recently developed SARS-CoV-2 candidate vaccines, natural protein-based nanoparticles well suited for multivalent antigen presentation and enhanced immune stimulation to elicit potent humoral and cellular immune responses are currently being investigated. This mini-review presents recent innovations in protein-based nanoparticle vaccines against SARS-CoV-2. The design and strategy of displaying antigenic domains, including spike protein, receptor-binding domain (RBD), and other domains on the surface of various protein-based nanoparticles and the performance of the developed nanoparticle-based vaccines are highlighted. In the final part of this review, we summarize and discuss recent advances in clinical trials and provide an outlook on protein-based nanoparticle vaccines.
APA, Harvard, Vancouver, ISO, and other styles
10

Hu, Yun, Daniel Smith, Zongmin Zhao, Theresa Harmon, Paul R. Pentel, Marion Ehrich, and Chenming Zhang. "Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine." Nanomedicine: Nanotechnology, Biology and Medicine 20 (August 2019): 102023. http://dx.doi.org/10.1016/j.nano.2019.102023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nanoparticle-based vaccines"

1

Hu, Yun. "Development of nanoparticle based nicotine vaccines for smoking cessation." Diss., Virginia Tech, 2015. http://hdl.handle.net/10919/73574.

Full text
Abstract:
Cigarette smoking is prevalent worldwide and has consistently been the top preventable cause of many serious diseases., which result in huge mortality, morbidity, and economic loss, in recent decades. In recent years, nicotine vaccines that can induce production of nicotine specific antibodies in human have emerged as a promising medicine to treat tobacco addiction. In the past decade, there have been numerous nicotine vaccine candidates evaluated in human clinical trials, including NicVaxNicVAX®, TA-NICTA-NIC®, Nic002NIC002®, NiccineNiccine®, and SEL-068SEL-068®. . However, traditional nicotine vaccine designs haves many disadvantages, including low immunogenicity, low specificity, difficulty in integration of molecular adjuvants, and short immune response persistence. To overcome the above limitations, in this study, various nanoparticle-based vaccine delivery systemsvaccine componentss have been developed and evaluated as potential delivery vehicles for vaccines against nicotine addiction. Firstly, a nicotine vaccine was synthesized by conjugating bovine serum albumin (BSA)-nicotine complex to the surface of nano-sized cationic liposome. Significantly higher anti-nicotine antibody titer was achieved in mice by liposome delivered nicotine vaccine compared with nicotine-BSA vaccine. Secondly, a novel nanoparticle (NP)-based delivery platform was constructed by incorporating a negatively charged nanohorn into cationic liposome to improve the stability of liposome and reduce nanoparticle flocculation. Subsequently, nicotine vaccine was constructed by conjugating nicotine-BSA complex to the surface of the nanohorn supported liposome (NsL). Marked improvement in stability in vitro and significant increase in titer of anti-nicotine antibodies were detected in nanohorn supported liposome ( NsL) delivered vaccine than liposome delivered vaccine. In addition, NsL nicotine vaccine exhibited good safety in mice after multiple injections. Thirdly, lipid- poly(lactic-co-glycolic acid) (PLGA) hybrid NPs were constructed as vaccine delivery system. due to the fact that nanohorn is not currently approved for clinical use, we substituted the nanohorn with poly(lactic-co-glycolic acid) (PLGA) nanoparticles and constructed PLGA-lipid hybrid nanoparticles. Preliminary results showed that PLGA-lipid hybrid NPs nanoparticles exhibited improved stability, better controlled release of antigens, as well as enhanced uptake by dendritic cell (DC). A lipid-PLGA hybrid NPnanoparticle was also developed that was structurally responsive to low pH challenge. The lipid shell of the hybrid nanoparticle was rapidly disintegrated under a low pH challenge, which resembles the acidic environment of endosomes in DCsdendritic cells. The hybrid NPs exhibited minimal antigen release in human serum at physiological pH, but a faster release of antigen from this NP compared to non-pH sensitive NPs was observed in DC. In the final study, hybrid NPnanoparticles with various cholesterol concentrations were constructed. Slower and more controlled release of antigens in both human serum and phosphate buffered saline were detected in nanoparticles with higher cholesterol content. However, nanoparticles containing higher cholesterol showed poorer stability due to increase fusion among NPnanoparticles. It was later found that PEGylation of NPs can effectively minimize fusion caused size increase after long term storage, leading to improved cellular uptake. The findings from this study on the nanohorn-lipids based nicotine vaccine as well as lipid-PLGA hybrid NPs may provide solid basis for future development of lipid-PLGA based nicotine vaccine.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
2

Hanson, Melissa C. (Melissa Catherine). "Enhancement of HIV vaccine efficacy via lipid nanoparticle-based adjuvants." Thesis, Massachusetts Institute of Technology, 2014. http://hdl.handle.net/1721.1/97975.

Full text
Abstract:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, February 2015..
Cataloged from PDF version of thesis. "December 2014."
Includes bibliographical references (pages 93-108).
Adjuvants are immunomodulators and/or formulations/delivery vehicles which enhance immune responses to vaccines. The lack of progress in the development of an HIV humoral vaccine is due, in part, to the absence of available adjuvants which can be sufficiently potent with minimal adverse side effects. The main goal of this thesis was to develop nanoparticles as HIV vaccine adjuvants. Building upon previous work in the Irvine lab, we determined the potency of lipid-coated microparticles was due in part to the in situ generation of antigen-displaying liposomes. Synthetic liposomes were nearly as potent as lipid-coated microparticles, but with a 10-fold greater antigen conjugation efficiency. We subsequently optimized unilamellar liposomes as delivery vehicles for surface-displayed HIV antigens. For vaccines with a recombinant gpl20 monomer (part of the HIV envelope trimer), immunization at 0 and 6 weeks with 65 nm or 150 nm diameter liposomes with 7.5 pmol gpl20 was found to induce strong anti-gp120 titers which competed with the broadly-neutralizing antibody VRC01. The second HIV antigen used was a peptide derived from the membrane proximal external region (MPER) of the gp41 protein. High-titer IgG responses to MPER required the presentation of MPER on liposomes and the inclusion of molecular adjuvants such as monophosphoryl lipid A. Anti-MPER humoral responses were further enhanced optimizing the MPER density to a mean distance of -10-15 nm between peptides on the liposomes surfaces. Lastly, we explored the adjuvant potential of cyclic dinucleotides (CDNs) with MPER liposome vaccines. Encapsulation of CDN in PEGylated liposomes enhanced its accumulation in draining lymph nodes (dLNs) 15-fold compared to unformulated cyclic dinucleotide. Liposomal CDN robustly induced type I interferon in dLNs, and promoted durable antibody titers comparable to a 30-fold larger dose of unformulated CDN without the systemic toxicity of the latter. This work defines several key properties of liposome formulations that promote durable, high-titer antibody responses against HIV antigens and demonstrates the humoral immunity efficacy of nanoparticulate delivery of cyclic dinucleotides, which is an approach broadly applicable to small molecule immunomodulators of interest for vaccines and immunotherapy.
by Melissa C. Hanson.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
3

Patel, Bindi Patel. "Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer." Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1523873757595623.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dhakal, Santosh. "Development and Evaluation of Nanoparticle-based Intranasal Inactivated Influenza Virus Vaccine Candidates in Pigs." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1529829066502348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Han, Yi. "Development and Evaluation of Mucoadhesive Chitosan Nanoparticle-based Salmonella Vaccine for Oral Delivery in Broiler Birds." The Ohio State University, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=osu1587571015936815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhao, Zongmin. "Factors that Affect the Immunogenicity of Lipid-PLGA Nanoparticle-Based Nanovaccines against Nicotine Addiction." Diss., Virginia Tech, 2017. http://hdl.handle.net/10919/88033.

Full text
Abstract:
Tobacco smoking has consistently been the leading cause of preventable diseases and premature deaths. Currently, pharmacological interventions have only shown limited smoking cessation efficacy and sometimes are associated with severe side effects. As an alternative, nicotine vaccines have emerged as a promising strategy to combating nicotine addiction. However, conventional conjugate nicotine vaccines have shown limited ability to induce a sufficiently strong immune response due to their intrinsic shortfalls. In this study, a lipid-poly(lactic-co-glycolic acid) (PLGA) nanoparticle-based next-generation nicotine vaccine has been developed to overcome the drawbacks of conjugate nicotine vaccines. Also, the influence of multiple factors, including nanoparticle size, hapten density, hapten localization, carrier protein, and molecular adjuvants, on its immunogenicity has been investigated. Results indicated that all these studied factors significantly affected the immunological efficacy of the nicotine nanovaccine. First, 100 nm nanovaccine was found to elicit a significantly higher anti-nicotine antibody titer than the 500 nm nanovaccine. Secondly, the high-density nanovaccine exhibited a better immunological efficacy than the low- and medium-density counterparts. Thirdly, the nanovaccine with hapten localized on both carrier protein and nanoparticle surface induced a significantly higher anti-nicotine antibody titer and had a considerably better ability to block nicotine from entering the brain of mice than the nanovaccines with hapten localized only on carrier protein or nanoparticle surface. Fourthly, the nanovaccines carrying cross reactive materials 197 (CRM197) or tetanus toxoid (TT) showed a better immunological efficacy than the nanovaccines using keyhole limpet hemocyanin (KLH) or KLH subunit as carrier proteins. Finally, the co-delivery of monophosphoryl lipid A (MPLA) and Resiquimod (R848) achieved a considerably higher antibody titer and brain nicotine reduction than only using MPLA or R848 alone as adjuvants. Collectively, the findings from this study may lead to a better understanding of the impact of multiple factors on the immunological efficacy of the hybrid nanoparticle-based nicotine nanovaccine. The findings may also provide significant guidance for the development of other drug abuse and nanoparticle-based vaccines. In addition, the optimized lipid-PLGA hybrid nanoparticle-based nicotine nanovaccine obtained by modulating the studied factors can be a promising candidate as the next-generation nicotine vaccine for treating nicotine addiction.
PHD
APA, Harvard, Vancouver, ISO, and other styles
7

Yang, Fan [Verfasser], and Frank [Akademischer Betreuer] Rösl. "Re-engineering a Nanoparticle Human Papillomavirus Prophylactic Vaccine Antigen Based on the Minor Capsid Protein L2 / Fan Yang ; Betreuer: Frank Rösl." Heidelberg : Universitätsbibliothek Heidelberg, 2020. http://d-nb.info/121816798X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yi-WenLiu and 劉怡彣. "Development of a biodegradable nanoparticle based vaccine for Clostridium difficile infection." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/43479618648331768996.

Full text
Abstract:
碩士
國立成功大學
微生物及免疫學研究所
104
Clostridium difficile is now considered to be one of the major causes of infectious diarrhea in healthcare systems worldwide. C. difficile infection is believed to be a toxin-mediated intestinal disease caused mainly by two large exotoxins, toxins A and B. In this study, we constructed a non-toxic recombinant protein, rTcdB, which consists of residues 1852-2363 of Toxin B receptor binding domain as a potential vaccine candidate. rTcdB was encased in nanoparticles (NPs) composed of γ-PGA and chitosan, which are made of natural materials, biodegradable, non-toxic and able to induce a high degree of immune response. Moreover, the NPs were recently reported as a mucosal adjuvant; it could induce a strong mucosal immunity in the gastrointestinal tract. We compared intraperitoneal injection and mucosal vaccination regimens and found that both methods provided mice full protection from lethal dose of C. difficile spore challenge. Protection was associated with high levels of toxin-neutralizing antibodies, and the rTcdB-encapsulating NPs elicited longer-lasting antibody responses than rTcdB with the conventional adjuvant, aluminum hydroxide. These results suggest that rTcdB is highly immunogenic when encapsulated by the safe and potent vaccine adjuvant NPs. In conclusion, this study demonstrates that prophylactic parenteral or oral vaccination with rTcdB-encapsulating NPs can provide protection from C. difficile infection.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Nanoparticle-based vaccines"

1

Bharali, Dhruba J., Shaker A. Mousa, and Yasmin Thanavala. "Micro- and Nanoparticle-Based Vaccines for Hepatitis B." In Advances in Experimental Medicine and Biology, 415–21. New York, NY: Springer New York, 2007. http://dx.doi.org/10.1007/978-0-387-72005-0_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Madkour, Loutfy H. "Application of Carbon Nanotubes in Cancer Vaccines as Drug Delivery Tools." In Nanoparticle-Based Drug Delivery in Cancer Treatment, 275–310. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003229674-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ilyinskii, Petr O., and Lloyd P. M. Johnston. "Nanoparticle-Based Nicotine Vaccine." In Biologics to Treat Substance Use Disorders, 249–78. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-23150-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zubair, Swaleha, Asim Azhar, Nazoora Khan, Ejaj Ahmad, Mohd Ajmal, and Mohammad Owais. "Nanoparticle-Based Mycosis Vaccine." In Methods in Molecular Biology, 169–211. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7104-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Akagi, Takami, Masanori Baba, and Mitsuru Akashi. "Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine." In Polymers in Nanomedicine, 31–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/12_2011_150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Diaz-Arévalo, Diana, and Mingtao Zeng. "Nanoparticle-based vaccines." In Nanopharmaceuticals, 135–50. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-817778-5.00007-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fujita, Y., and H. Taguchi. "Nanoparticle-Based Peptide Vaccines." In Micro and Nanotechnology in Vaccine Development, 149–70. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-323-39981-4.00008-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Saravanan, Muthupandian, Kebret Duche, Tsehaye Asmelash, Araya Gebreyesus, Anima Nanda, and Selvaraj Arokiyaraj. "Nanomedicine as a Newly Emerging Approach Against Multidrug-Resistant Tuberculosis (MDR-TB)." In Integrating Biologically-Inspired Nanotechnology into Medical Practice, 50–73. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0610-2.ch003.

Full text
Abstract:
Emergence of MDR-TB is highly associated with morbidity and mortality and it needs high concerns about the possibility of a future TB epidemic as limited therapeutic options are available. The current treatment against TB needs daily administration for at least 6 months. That in turn leads to the development and spread of drug-resistant TB. Plenty of work has been done in nanomedicine that provides hope to encounter TB effectively. In the developing world the development of nanoparticle-based aerosol vaccines for tuberculosis has potential applications using on a large scale at relatively low cost, and particularly attractive for use. This book review examines the current TB diagnostic assays and treatment by nanotechnologies and highlight recent advances in Anti-TB Drug (ATD) delivery systems and anti-TB drug encapsulation. It also discusses the impact of the nanoparticles as an emerging treatment against MDR-TB and discusses the current knowledge and potential nanomedicine to improve MDR-TB therapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Saravanan, Muthupandian, Kebret Duche, Tsehaye Asmelash, Araya Gebreyesus, Anima Nanda, and Selvaraj Arokiyaraj. "Nanomedicine as a Newly Emerging Approach Against Multidrug-Resistant Tuberculosis (MDR-TB)." In Biomedical Engineering, 941–60. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-3158-6.ch041.

Full text
Abstract:
Emergence of MDR-TB is highly associated with morbidity and mortality and it needs high concerns about the possibility of a future TB epidemic as limited therapeutic options are available. The current treatment against TB needs daily administration for at least 6 months. That in turn leads to the development and spread of drug-resistant TB. Plenty of work has been done in nanomedicine that provides hope to encounter TB effectively. In the developing world the development of nanoparticle-based aerosol vaccines for tuberculosis has potential applications using on a large scale at relatively low cost, and particularly attractive for use. This book review examines the current TB diagnostic assays and treatment by nanotechnologies and highlight recent advances in Anti-TB Drug (ATD) delivery systems and anti-TB drug encapsulation. It also discusses the impact of the nanoparticles as an emerging treatment against MDR-TB and discusses the current knowledge and potential nanomedicine to improve MDR-TB therapy.
APA, Harvard, Vancouver, ISO, and other styles
10

Krishna Rao, Balaga Venkata, Aditi Pradhan, Sneha Singh, and Abhimanyu Dev. "An Overview on Nanoparticulate Drug Delivery System for its Specific and Targeted Effects in Various Diseases." In Nanoparticles and Nanocarriers-Based Pharmaceutical Formulations, 55–92. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815049787122010005.

Full text
Abstract:
In modern-day medicine, nanoparticles and nanocarriers are rapidly evolving fields in therapeutics and are the building blocks of nanomedicine, which emphasize the use of nanoscale particles that have a wide array of functions from working as a diagnostic tool to the screening, monitoring, and controlling of various diseases to the delivery of drugs at specific targets in a controlled manner. With the advancement in technologies, it is proven that nanoparticles have a greater potential in wide biomedical applications. Due to their ability to bind with both hydrophobic and lyophilic substances, lower particle size, higher carrier capacity, nanoparticles serve as a favorable platform for specific and targeted drug delivery in disease treatment. Nanoformulations can improve the safety, pharmacokinetic characteristics, and bioavailability of administered drugs, and can improve the therapeutic effect when compared with conventional therapies. Besides, nanoparticles may also be effective in delivering nucleotides, vaccines, and recombinant proteins. Several varieties of nanoparticles are available: different metal and polymeric nanoparticles like gold/silver nanoparticles and micelles, dendrimers. Carbon-derived nanoparticles like quantum dots, carbon tubes, and many other nano assemblies. Numerous nanocarriers, nanoparticle-based drug delivery systems, and drug targeting systems are either developed or under development. In this chapter, we will emphasize mainly the specific and targeted nanoparticles and the use of various nanocarriers for the targeted delivery of drugs in various diseases. The opportunities and challenges of using nanoparticles/nanocarriers in targeted delivery along with its clinical applications are also discussed here.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nanoparticle-based vaccines"

1

Steinmetz, Nicole F., Jonathan K. Pokorski, Steven N. Fiering, P. Jack Hoopes, Sourabh Shukla, Oscar A. Ortega-Rivera, Steven King, and Cyril J. Empig. "Abstract S05-02: Plant viral nanoparticle-based adjuvants for cancer immunotherapy and COVID-19 vaccines." In Abstracts: AACR Virtual Meeting: COVID-19 and Cancer; February 3-5, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1557-3265.covid-19-21-s05-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kim, Hyunjoon, Peter Larson, Tamara A. Kucaba, Katherine A. Murphy, David M. Ferguson, Thomas S. Griffith, and Jayanth Panyam. "Abstract 718: Nanoparticle-based tumor cell lysate vaccine for cancer immunotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-718.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Niu, Lin, Leonard Chu, Kris Hansen, and Jayanth Panyam. "Abstract A51: Intradermal delivery of polymeric nanoparticle based vaccine formulation using a hollow microneedle system." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-a51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Neuhaus, Vanessa, Katharina Schwarz, Wolfgang Koch, Katherina Sewald, Vidadi Yusibov, and Armin Braun. "Immunotoxic Characterization Of A Nanoparticle-Based Inhalable Influenza Vaccine In Murine And Human Precision Cut Lung Slices." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nanoparticle-based vaccines' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography